The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

被引：2
|
作者：
Carvajal, Luis A. [1 ]
McKeown, Michael R. [2 ]
Hood, Tressa [2 ]
Guo, Linlin [2 ]
Lin, Charles Y. [2 ]
DiMartino, Jorge F. [1 ]
机构：
[1] Kronos Bio Inc, San Mateo, CA USA
[2] Kronos Bio Inc, Cambridge, MA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
616
引用
收藏
页数：3
相关论文
共 50 条
  • [41] AC220, a uniquely potent and selective FLT3 inhibitor, provides sustained protection in a FLT3 ITD driven model of acute myeloid leukemia
    Belli, Barbara
    Brigham, Daniel
    Breider, Michael
    Bhagwat, Shripad
    Armstrong, Robert
    CANCER RESEARCH, 2009, 69
  • [42] FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
    Seipel, Katja
    Mandhair, Harpreet
    Bacher, Ulrike
    Pabst, Thomas
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (04) : 2946 - 2960
  • [43] Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
    Hu, Chuhong
    Zhang, Yvyin
    Yang, Jie
    Xu, Yanli
    Deng, Tingfen
    Li, Yumiao
    Xu, Shilin
    Wang, Shunqing
    Wang, Peihong
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [44] Maturation Induced by FLT3 Inhibitor Therapy of Acute Myeloid Leukemia: Morphologic and Immunophenotypic Characteristics
    Arries, Cade D.
    Yohe, Sophia L.
    LABORATORY MEDICINE, 2020, 51 (05) : 478 - 483
  • [45] Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia
    Sawyers, CL
    CANCER CELL, 2002, 1 (05) : 413 - 415
  • [46] FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
    Pulte, E. Dianne
    Norsworthy, Kelly J.
    Wang, Yaping
    Xu, Qing
    Qosa, Hisham
    Gudi, Ramadevi
    Przepiorka, Donna
    Fu, Wentao
    Okusanya, Olanrewaju O.
    Goldberg, Kirsten B.
    De Claro, R. Angelo
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3515 - 3521
  • [47] Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
    Wei, Tian-Hua
    Wang, Zi-Xuan
    Lu, Meng-Yi
    Xu, Yu-Jing
    Yang, Jin
    Ni, Xing-Feng
    Cheng, Yang
    Zhang, Meng-Yuan
    Liu, Jia-Chuan
    Li, Qing-Qing
    Cai, Jiao
    Chen, Zi-Jun
    Kang, Ji-Bo
    Li, Nan
    Dai, Wei-Chen
    Ding, Ning
    Yu, Yan-Cheng
    Leng, Xue-Jiao
    Xue, Xin
    Wang, Xiao-Long
    Sun, Shan-Liang
    Yang, Ye
    Li, Nian-Guang
    Shi, Zhi-Hao
    JOURNAL OF MEDICINAL CHEMISTRY, 2024,
  • [48] HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia
    Kim, JiSook
    Bae, InHwan
    Choi, JaeYul
    Kim, MinJeong
    Byun, JooYun
    Moon, Mijin
    Lee, EunYoung
    Kim, Yu-Yon
    Kang, Hyun Jeong
    Kim, Eunyoung
    Jung, SunYoung
    Ahn, YoungGil
    Kim, YoungHoon
    Suh, Kwee Hyun
    CANCER RESEARCH, 2019, 79 (13)
  • [49] GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
    Xinhua Xiao
    Peihong Wang
    Weina Zhang
    Jiayi Wang
    Mansi Cai
    Hua Jiang
    Yingli Wu
    Huizhuang Shan
    Cancer Cell International, 23
  • [50] The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
    Minson, Katherine A.
    Smith, Catherine C.
    DeRyckere, Deborah
    Libbrecht, Clara
    Lee-Sherick, Alisa B.
    Huey, Madeline G.
    Lasater, Elisabeth A.
    Kirkpatrick, Gregory D.
    Stashko, Michael A.
    Zhang, Weihe
    Jordan, Craig T.
    Kireev, Dmitri
    Wang, Xiaodong
    Frye, Stephen V.
    Earp, H. Shelton
    Shah, Neil P.
    Graham, Douglas K.
    JCI INSIGHT, 2016, 1 (03)
12345